| 1 |
Huang JF, Mao YL, Millis JM. Government policy and organ transplantation in China[J]. Lancet, 2008, 372(9654): 1937-1938.
|
| 2 |
黄洁夫. 2020中国器官移植发展报告[M]. 北京：中国科学技术出版社，2020: 13-26.
|
| 3 |
Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs[J]. Gastroenterology, 2011，140(1)：51-64.
|
| 4 |
Rodríguez Faba O，Boissier R，Budde K，et al. European Association of Urology guidelines on renal transplantation：update 2018[J]. Eur Urol Focus，2018，4(2)：208-215.
|
| 5 |
Lim MA, Bloom RD. How to maximize graft survival[J]. Curr Opin Organ Transplant, 2022, 28(1): 55-63.
|
| 6 |
Bergan S, Brunet M, Hesselink DA, et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology[J]. Ther Drug Monit, 2021, 43(2): 150-200.
|
| 7 |
中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植，2019, 10(3): 213-226.
|
| 8 |
European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection[J]. Lancet, 1995, 345(8961): 1321-1325.
|
| 9 |
Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection[J]. Transplantation, 2000, 69(11): 2405-2409.
|
| 10 |
Wiesner RH, Shorr JS, Steffen BJ, et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C[J]. Liver Transplant, 2005, 11(7): 750-759.
|
| 11 |
Naffouje R, Grover P, Yu HY, et al. Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story[J]. Cancers, 2019, 11(9): 1346.
|
| 12 |
Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil[J]. Drugs, 2005, 65(8): 1037-1050.
|
| 13 |
国家药典委员会. 中华人民共和国药典临床用药须知：2020年版. 化学药和生物制品卷[M]. 北京：中国医药科技出版社，2022: 1622-1628, 1638-1640.
|
| 14 |
Abd Rahman AN, Tett SE, Staatz CE. How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease？[J]. Clin Pharmacokinet, 2014, 53(3): 227-245.
|
| 15 |
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet, 2007, 46(1): 13-58.
|
| 16 |
Kant S, Kronbichler A, Geetha D. Principles of immunosuppression in the management of kidney disease: core curriculum 2022[J]. Am J Kidney Dis, 2022, 80(3): 393-405.
|
| 17 |
Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update[J]. Arch Toxicol, 2014, 88(7): 1351-1389.
|
| 18 |
Shipkova M, Armstrong VW, Weber L, et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients[J]. Ther Drug Monit, 2002, 24(3): 390-399.
|
| 19 |
Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity？[J]. Transplant Proc, 2007, 39(1): 88-93.
|
| 20 |
Cattaneo D, Cortinovis M, Baldelli S, et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients[J]. Clin J Am Soc Nephrol, 2007, 2(6): 1147-1155.
|
| 21 |
Jonge H, Naesens M, Kuypers D. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation[J]. Ther Drug Monit, 2009, 31(4): 416-435.
|
| 22 |
Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients[J]. Am J Transplant, 2004, 4(2): 231-236.
|
| 23 |
Ettenger R, Bartosh S, Choi L, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients[J]. Pediatr Transplant, 2005, 9(6): 780-787.
|
| 24 |
Holt D. Monitoring mycophenolic acid[J]. Ann Clin Biochem, 2002, 39(Pt 3): 173-183.
|
| 25 |
Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil[J]. Clin Transplant, 2005, 19(2): 199-206.
|
| 26 |
Echenique IA, Penugonda S, Stosor V, et al. Diagnostic yields in solid organ transplant recipients admitted with diarrhea[J]. Clin Infect Dis, 2015, 60(5): 729-737.
|
| 27 |
Angarone M, Ison MG. Diarrhea in solid organ transplantrecipients[J]. Curr Opin Infect Dis, 2015, 28(4): 308-316.
|
| 28 |
Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality[J]. Am J Kidney Dis, 2008, 51(3): 478-486.
|
| 29 |
Aulagnon F, Scemla A, DeWolf S, et al. Diarrhea after kidney transplantation: a new look at a frequent symptom[J]. Transplantation, 2014, 98(8): 806-816.
|
| 30 |
Shin HS, Chandraker A. Causes and management of postrenal transplant diarrhea: an underappreciated cause of transplant-associated morbidity[J]. Curr Opin Nephrol Hypertens, 2017, 26(6): 484-493.
|
| 31 |
Maes B, Hadaya K, De Moor B, et al. Severe diarrhea in renal transplant patients: results of the DIDACT study[J]. Am J Transplant, 2006, 6(6): 1466-1472.
|
| 32 |
Wagner M, Earley AK, Webster AC, et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients[J/OL]. Cochrane Database Syst Rev, 2015, 12: CD007746. [2015-12-03].
URL
|
| 33 |
Zazgornik J. Azathioprine induced macrocytosis and red cell aplasia in renal transplant patients[J]. Nephrol Dial Transplant, 1997, 12(3): 628.
|
| 34 |
Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study[J]. Am J Transplant, 2004, 4(2): 237-243.
|
| 35 |
van Gelder T, Hesselink DA. Mycophenolate revisited[J]. Transpl Int, 2015, 28(5): 508-515.
|
| 36 |
Ortega F, Sánchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium[J]. Transplantation, 2011, 92(4): 426-432.
|
| 37 |
Kuypers DRJ, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients[J]. Clin Ther, 2008, 30(4): 673-683.
|
| 38 |
Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity[J]. Am J Transplant, 2006, 6(1): 121-128.
|
| 39 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J]. 中华消化外科杂志，2022, 21(4): 433-443.
|
| 40 |
Di Maira T, Little EC, Berenguer M. Immunosuppression in liver transplant[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101681.
|
| 41 |
Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1): 3-26.
|
| 42 |
European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation[J]. J Hepatol, 2016, 64(2): 433-485.
|
| 43 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2019版)[J]. 中华移植杂志(电子版), 2019, 13(3): 187-194.
|
| 44 |
Tan PS, Muthiah MD, Koh T, et al. Asian Liver Transplant Network clinical guidelines on immunosuppression in liver transplantation[J]. Transplantation, 2019, 103(3): 470-480.
|
| 45 |
Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study[J]. Am J Transplant, 2011, 11(5): 965-976.
|
| 46 |
Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT’ study[J]. Am J Transplant, 2009, 9(2): 327-336.
|
| 47 |
Boillot O, Seket B, Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study[J]. Liver Transplant, 2009, 15(11): 1426-1434.
|
| 48 |
Azhie A, Sheth P, Hammad A, et al. Metabolic complications in liver transplantation recipients: how we can optimize long-term survival[J]. Liver Transplant, 2021, 27(10): 1468-1478.
|
| 49 |
Bhat M, Usmani SE, Azhie A, et al. Metabolic consequences of solid organ transplantation[J]. Endocr Rev, 2021, 42(2): 171-197.
|
| 50 |
Shen T, Zhuang L, Sun XD, et al. Expert consensus on management of metabolic disease in Chinese liver transplant recipients[J]. World J Gastroenterol, 2020, 26(27): 3851-3864.
|
| 51 |
Goralczyk AD, Bari N, Abu-Ajaj W, et al. Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials[J]. Am J Transplant, 2012, 12(10): 2601-2607.
|
| 52 |
De Simone P, Carrai P, Coletti L, et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: a propensity score-matched analysis in liver transplantation[J]. Transplant Proc, 2018, 50(10): 3615-3620.
|
| 53 |
Van Laecke S, Malfait T, Schepers E, et al. Cardiovascular disease after transplantation: an emerging role of the immune system[J]. Transpl Int, 2018, 31(7): 689-699.
|
| 54 |
van Leuven SI, Kastelein JJP, Allison AC, et al. Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles？[J]. Cardiovasc Res, 2006, 69(2): 341-347.
|
| 55 |
Giusto M, Berenguer M, Merkel C, et al. Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up[J]. Transplantation, 2013, 95(9): 1148-1153.
|
| 56 |
Sharma P, Bari K. Chronic kidney disease and related long-term complications after liver transplantation[J]. Adv Chronic KidneyDis, 2015, 22(5): 404-411.
|
| 57 |
Shao ZY, Yan LN, Wang WT, et al. Prophylaxis of chronic kidney disease after liver transplantation—experience from West China[J]. World J Gastroenterol, 2012, 18(9): 991-998.
|
| 58 |
Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment[J]. Transplantation, 2001, 72(12): 1934-1939.
|
| 59 |
Pham PT T, Lunsford KE, Bunnapradist S, et al. Simultaneous liver-kidney transplantation or liver transplantation alone for patients in need of liver transplantation with renal dysfunction[J]. Curr Opin Organ Transplant, 2016, 21(2): 194-200.
|
| 60 |
Kim DG, Kim SH, Hwang S, et al. Safety of tacrolimus monotherapy within 12 months after liver transplantation in the era of reduced tacrolimus and mycophenolate mofetil: national registry study[J]. J Clin Med, 2022, 11(10): 2806.
|
| 61 |
Schmeding M, Kiessling A, Neuhaus R, et al. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial[J]. Transplantation, 2011, 92: 923-929.
|
| 62 |
Hao JC, Wang WT, Yan LN, et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation[J]. World J Gastroenterol, 2014, 20(32): 11356-11362.
|
| 63 |
Beckebaum S, Cicinnati VR. Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late？[J]. Dig Dis Sci, 2011, 56(1): 4-6.
|
| 64 |
Haywood S, Abecassis M, Levitsky J. The renal benefit of mycophenolate mofetil after liver transplantation[J]. Clin Transplant, 2011, 25(1): E88-E95.
|
| 65 |
Charlton M, Levitsky J, Aqel B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5): 727-743.
|
| 66 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝移植受者肾损伤管理专家共识(2017版)[J]. 中华移植杂志(电子版), 2017, 11(3): 130-137.
|
| 67 |
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA, 2011, 306(17): 1891-1901.
|
| 68 |
Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology[J]. Curr Opin Organ Transplant, 2014, 19(3): 253-260.
|
| 69 |
Chen K, Sheng JX, Ma BY, et al. Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients[J]. Transplantation, 2019, 103(5): 929-937.
|
| 70 |
Heits N, Heinze T, Bernsmeier A, et al. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts[J]. BMC Cancer, 2016, 16: 322.
|
| 71 |
Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial[J]. Am J Transplant, 2012, 12(3): 694-705.
|
| 72 |
Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6): 1193-1199.
|
| 73 |
Gonzalez-Cao M, Puertolas T, Riveiro M, et al. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)[J]. J Immunother Cancer, 2021, 9(3): e001664.
|
| 74 |
Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation[J]. Transplantation, 2005, 79(11): 1575-1580.
|
| 75 |
Tannuri U, Gibelli NEM, Maksoud-Filho JG, et al. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center[J]. Pediatr Transplant, 2007, 11(1): 82-86.
|
| 76 |
Kelly DA, Bucuvalas JC, Alonso EM, et al. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transplant, 2013, 19(8): 798-825.
|
| 77 |
中华医学会器官移植学分会. 中国儿童肝移植操作规范(2019版)[J]. 中华移植杂志(电子版), 2019, 13(3): 181-186.
|
| 78 |
Vincenzi R, Fonseca EA, Roda KMO, et al. Current practice in immunosuppression in pediatric liver transplantation[J]. Curr Pharm Des, 2020, 26(28): 3402-3405.
|
| 79 |
Wei Y, Wu D, Chen Y, et al. Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation[J]. Front Pharmacol, 2022, 13: 1002628.
|
| 80 |
Smith SK, Miloh T. Pediatric liver transplantation[J]. Clin Liver Dis, 2022, 26(3): 521-535.
|
| 81 |
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3): S1-S155.
|
| 82 |
EAU Guidelines Office, EAU Guidelines on Renal Transplantation[EB/OL]. [2023-07-22]
URL
|
| 83 |
中华医学会器官移植学分会，中国医师协会器官移植医师分会. 中国肾移植受者免疫抑制治疗指南(2016版)[J]. 器官移植，2016, 7(5): 327-331.
|
| 84 |
中华医学会器官移植学分会. 儿童肾移植技术操作规范(2019版)[J]. 器官移植，2019, 10(5): 499-504.
|
| 85 |
Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation[J]. Am J Transplant, 2004, 4(7): 1079-1083.
|
| 86 |
Li PM, Shuker N, Hesselink DA, et al. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients？[J]. Transpl Int, 2014, 27(10): 994-1004.
|
| 87 |
Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation[J]. N Engl J Med, 2007, 357(25): 2562-2575.
|
| 88 |
Claes K, Meier-Kriesche HU, Schold JD, et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study[J]. Nephrol Dial Transplant, 2012, 27(2): 850-857.
|
| 89 |
季曙明，谢轲楠，陈劲松，等. 采用移植肾活检评估不同剂量吗替麦考酚酯对移植肾存活的影响[J]. 医学研究生学报，2014, 27(05): 491-6.
|
| 90 |
Fu L, Huang Z, Song T, et al. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation[J]. Transpl Infect Dis, 2014, 16(5): 760-766.
|
| 91 |
Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation[J]. Am J Transplant, 2007, 7(11): 2496-2503.
|
| 92 |
Chen LP, Bai HW, Jin HL, et al. Outcomes in kidney transplantation with mycophenolate mofetil-based maintenance immunosuppression in China: a large-sample retrospective analysis of a national database[J]. Transpl Int, 2020, 33(7): 718-728.
|
| 93 |
van Gelder T, Silva HT, de Fijter H, et al. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation[J]. Ther Drug Monit, 2011, 33(2): 155-164.
|
| 94 |
Ding C, Xue W, Tian P, et al. Outcomes of standard dose EC-MPS with low exposure to CsA in DCD renal transplantation recipients with DGF[J]. Int J Clin Pract, 2015, 69: 8-15.
|
| 95 |
Neuberger JM, Bechstein WO, Kuypers DRJ, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group[J]. Transplantation, 2017, 101(4S): S1-S56.
|
| 96 |
Yesil EE, Yilmaz Y, Yesil A, et al. Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: a cross-sectional study using FibroScan[J]. Hepatol Forum, 2023, 4(1): 14-18.
|
| 97 |
陈怀周，朱有华，眭维国，等. 肾移植术后代谢综合征发病率及其危险因素临床研究[J]. 国际泌尿系统杂志，2008, 28(3): 293-296.
|
| 98 |
Brunkhorst LC, Fichtner A, Höcker B, et al. Efficacy and safety of an everolimus-vs. a mycophenolate mofetil-based regimen in pediatric renal transplant recipients[J]. PLoS One, 2015, 10(9): e0135439.
|
| 99 |
Lederer SR, Friedrich N, Banas B, et al. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation[J]. Clin Transplant, 2005, 19(2): 168-174.
|
| 100 |
Filler G, Todorova EK, Bax K, et al. Minimum mycophenolic acid levels are associated with donor-specific antibody formation[J]. Pediatr Transplant, 2016, 20(1): 34-38.
|
| 101 |
Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year[J]. J Am Soc Nephrol, 2006, 17(1): 305-312.
|
| 102 |
Nankivell BJ, P′Ng CH, O′Connell PJ, et al. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras[J]. Transplantation, 2016, 100(8): 1723-1731.
|
| 103 |
Ekberg H, van Gelder T, Kaplan B, et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation[J]. Transplantation, 2011, 92(1): 82-87.
|
| 104 |
Wang XY, Zhang XX, Lu S, et al. Protective effect of mycophenolate mofetil on residual renal function in peritoneal dialysis patients: an open label feasibility study[J]. Nephrology, 2017, 22(12): 954-960.
|
| 105 |
Heemann U, Kliem V, Budde K, et al. Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the TranCept STAY study[J]. Clin Transplant, 2012, 26(6): 919-926.
|
| 106 |
潘国政，戴帅，邱成，等. 肾移植术后减量他克莫司联合加量吗替麦考酚酯的疗效和安全性[J]. 器官移植，2016, 7(2): 124-127.
|
| 107 |
Ciancio G, Gaynor JJ, Guerra G, et al. Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low-dose corticosteroids in primary kidney transplantation: 18-year results[J]. Clin Transplant, 2020, 34(12): e14123.
|
| 108 |
张杰，成富民，朱昆仑，等. 不同霉酚酸剂型在儿童肾移植不同年龄段的暴露差异[J]. 器官移植，2022, 13(3): 356-362.
|
| 109 |
张鲁予，张荻，丰永花，等. 低剂量兔抗人胸腺细胞免疫球蛋白用于儿童肾移植诱导治疗的临床研究[J]. 中华器官移植杂志，2023, 44(2): 81-86.
|
| 110 |
郭志良，萨如拉，朱兰，等. 儿童肾移植术后急性排斥反应相关影响因素的单中心队列研究[J]. 中华器官移植杂志，2023, 44(2): 68-74.
|
| 111 |
丛雯亓，吴晴航，崔瑜，等. 儿童肾移植受者移植术后一年内发生急性排斥反应的影响因素及预后分析[J]. 中华器官移植杂志，2023, 44(2): 94-101.
|
| 112 |
赵闻雨，付嘉钊，李雨虹，等. 儿童肾移植术后急性排斥反应的危险因素分析[J]. 中华器官移植杂志，2023, 44(2): 87-93.
|
| 113 |
Kuypers DRJ, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation[J]. Clin J Am Soc Nephrol, 2010, 5(2): 341-358.
|
| 114 |
Gaston RS, Kaplan B, Shah T, et al. Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the opticept trial[J]. Am J Transplant, 2009, 9(7): 1607-1619.
|
| 115 |
van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial[J]. Transplantation, 2008, 86(8): 1043-1051.
|
| 116 |
Kuypers DR, Ekberg H, Grinyó J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of ciclosporin in renal transplant recipients[J]. Clin Pharmacokinet, 2009, 48(5): 329-341.
|
| 117 |
Gourishankar S, Houde I, Keown PA, et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation[J]. Clin J Am Soc Nephrol, 2010, 5(7): 1282-1289.
|
| 118 |
Meur Y, Borrows R, Pescovitz M, et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting[J]. Transplant Rev, 2011, 25: 58-64.
|
| 119 |
van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation[J]. Transplantation, 1999, 68(2): 261-266.
|
| 120 |
Hale MD, Nicholls AJ, Bullingham RES, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation[J]. Clin Pharmacol Ther, 1998, 64(6): 672-683.
|
| 121 |
Wang PL, Xie HC, Zhang QW, et al. Population pharmacokinetics of mycophenolic acid in renal transplant patients: a comparison of the early and stable posttransplant stages[J]. Front Pharmacol, 2022, 13: 859351.
|
| 122 |
David-Neto E, Pereira LM, Kakehashi E, et al. The need of mycophenolic acid monitoring in long-term renal transplants[J]. Clin Transplant, 2005, 19(1): 19-25.
|
| 123 |
Kikuchi M, Tanaka M, Takasaki S, et al. Comparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients[J]. J Pharm Health Care Sci, 2018, 4(1): 1-5.
|
| 124 |
Schutz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites[J]. Transplant Proc, 1998, 30(4): 1185-1187.
|
| 125 |
李佳，孙萍萍，傅茜，等. 高效液相色谱法与酶放大免疫测定法检测肾移植后血麦考酚酸浓度的比较[J]. 中华器官移植杂志，2014, 35(9): 528-532.
|
| 126 |
Weber LT, Shipkova M, Armstrong VW, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy[J]. Clin Chem, 2002, 48(3): 517-525.
|
| 127 |
王华彬，满江位，胡伟，等. 霉酚酸血药浓度监测在肾移植受者中的应用进展[J]. 医学综述，2020, 26(4): 652-657.
|
| 128 |
de Winter BC, van Gelder T, Glander P, et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients[J]. Clin Pharmacokinet, 2008, 47(12): 827-838.
|
| 129 |
Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring？[J]. Ther Drug Monit, 2003, 25(2): 137-157.
|
| 130 |
Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus[J]. Clin Chem, 2002, 48(9): 1497-1504.
|
| 131 |
Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure[J]. Transplant Rev, 2011, 25(2): 47-57.
|
| 132 |
Yao X, Huang H, Wei C, et al. Limited sampling strategy for mycophenolic acid in chinese kidney transplant recipients receiving enteric-coated mycophenolate sodium and tacrolimus during the early posttransplantation phase[J]. Ther Drug Monit, 2015, 37(4): 516-523.
|
| 133 |
Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range[J]. Liver Transplant, 2004, 10(4): 492-502.
|
| 134 |
中国药师协会. 医疗机构国家组织集中采购药品管理中国专家共识[J]. 中国新药杂志，2023, 32(3): 311-322.
|
| 135 |
广东省药学会. 广东省医疗机构落实药品集采科学管理专家建议[EB/OL]. (2022-10-28)[2023-07-31].
URL
|
| 136 |
湖北省医院协会药事管理专业委员会. 湖北省医疗机构落实药品集中采购工作药学专家建议[J]. 医药导报，2021, 40(12): 1615-1618.
|
| 137 |
河南省药学会. 河南省医疗机构落实药品集中采购政策药学专家共识[EB/OL]. (2022-07-12)[2023-07-31].
URL
|
| 138 |
《辽宁省医疗机构执行药品集中采购政策专家共识》起草专家组. 辽宁省医疗机构执行药品集中采购政策专家共识[J]. 实用药物与临床，2022, 25(9): 769-772.
|
| 139 |
山东省医院协会药物经济学专业委员会. 山东省医疗机构落实药品集中带量采购政策的药学专家共识(2022)[J]. 山东医药，2022, 62(21): 113-115.
|
| 140 |
陕西省药学会. 西北五省医疗机构落实药品集中带量采购科学管理专家共识[EB/OL]. (2022-08-25)[2023-07-31].
URL
|
| 141 |
Harrison JJ, Schiff JR, Coursol CJ, et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective[J]. Transplantation, 2012, 93(7): 657-665.
|
| 142 |
Li XX, Yin JY, Tang J, et al. Determining the balance between drug efficacy and safety by the network and biological system profile of its therapeutic target[J]. Front Pharmacol, 2018, 9: 1245.
|
| 143 |
Narrow Therapeutic Index Drugs[EB/OL]. [2023-09-06].
URL
|
| 144 |
上海医药行业协会. 窄治疗指数药物文献汇编[J]. 上海医药，2020, 41(增刊2): 22-24.
|
| 145 |
Kocis PT, Vrana KE. Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions[J]. Med Cannabis Cannabinoids, 2020, 3(1): 61-73.
|
| 146 |
American College of Clinical Pharmacy, Welty TE, Hilaire ML, et al. Guidelines for therapeutic interchange—2022[J]. J Am Coll Clin Pharm, 2022, 5(4): 476-483.
|
| 147 |
U. S. Food and Drug Administration. Pharmacometric approach to define narrow therapeutic index (NTI) drugs & evaluate bioequivalence (BE) criteria for NTI drugs[EB/OL]. [2023-08-21].
URL
|
| 148 |
U. S. Food and Drug Administration. FY2015 regulatory science research report: narrow therapeutic index drugs[EB/OL]. (2017-05-09)[2023-07-22].
URL
|
| 149 |
U. S. Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application[EB/OL]. (2022-02-24)[2023-07-22].
URL
|
| 150 |
国家药品监督管理局药品审评中心. 窄治疗指数药物生物等效性研究技术指导原则[EB/OL]. (2020-12-31) [2023-07-22].
URL
|
| 151 |
European Medicines Agency. Guideline on the investigation of bioequivalence[EB/OL]. (2010-01-20)[2023-07-22].
URL
|
| 152 |
World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fifth report[EB/OL]. [2023-07-22].
URL
|
| 153 |
国家药典委员会. 中华人民共和国药典-四部(2020年版)[M]. 北京：中国医药科技出版社，2020: 464.
|
| 154 |
国家药典委员会. 中华人民共和国药典-四部(2015年版)[M]. 北京：中国医药科技出版社，2015: 360.
|
| 155 |
Elangovan E. Bioequivalence guidelines requirements for orally administered generics (IR products) in gulf cooperation council countries, European Union and United States of America[J]. J Bioequiv Availab, 2019, 11(1): 6-13.
|
| 156 |
The United States Pharmacopeial. United States Pharmacopeia(2023)[M/OL]. Rockville, MD: United States Pharmacopeia, 2023.
URL
|
| 157 |
国家药典委员会. 中华人民共和国药典一二部(2020年版)[M]. 北京：中国医药科技出版社，2020: 452.
|
| 158 |
Habet S. Narrow Therapeutic Index drugs: clinical pharmacology perspective[J]. J Pharm Pharmacol, 2021, 73(10): 1285-1291.
|
| 159 |
Sarpatwari A, Lee MP, Gagne JJ, et al. Generic versions of narrow therapeutic index drugs: a national survey of pharmacists′ substitution beliefs and practices[J]. Clin Pharmacol Ther, 2018, 103(6): 1093-1099.
|
| 160 |
陈震，杨建红，张彦彦，等. 影响我国化学药品仿制药质量因素的问卷调查分析[J]. 中国新药杂志，2017, 26(13): 1477-1483.
|
| 161 |
Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants[J]. Am J Transplant, 2003, 3(10): 1211-1215.
|
| 162 |
van Gelder T, ESOT Advisory Committee on Generic Substitution. European Society for Organ Transplantation advisory committee recommendations on generic substitution of immunosuppressive drugs[J]. Transpl Int, 2011, 24(12): 1135-1141.
|
| 163 |
Uber PA, Ross HJ, Zuckermann AO, et al. Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory[J]. J Heart Lung Transplant, 2009, 28(7): 655-660.
|